Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial

Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)

Diabetes Obesity and Metabolism ◽

10.1111/dom.12937 ◽

2017 ◽

Vol 19 (7) ◽

pp. 1024-1031 ◽

Cited By ~ 57

Author(s):

Paolo Pozzilli ◽

Paul Norwood ◽

Esteban Jódar ◽

Melanie J. Davies ◽

Tibor Ivanyi ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Randomized Trial ◽

Receptor Agonist ◽

Daily Insulin ◽

Glucagon Like Peptide ◽

Response to Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509–2518

Diabetes Care ◽

10.2337/dci21-0004 ◽

2021 ◽

Vol 44 (11) ◽

pp. e196-e197

Author(s):

Julio Rosenstock

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Insulin Therapy ◽

Randomized Trial ◽

Diabetes Care ◽

Receptor Agonist ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509–2518

Diabetes Care ◽

10.2337/dc20-2987 ◽

2021 ◽

Vol 44 (11) ◽

pp. e194-e195 ◽

Cited By ~ 1

Author(s):

Chinmay S. Marathe ◽

Karen L. Jones ◽

Christopher K. Rayner ◽

Tongzhi Wu ◽

Michael Horowitz

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Insulin Therapy ◽

Randomized Trial ◽

Diabetes Care ◽

Receptor Agonist ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial

Diabetes Care ◽

10.2337/dc19-2316 ◽

2020 ◽

Vol 43 (10) ◽

pp. 2509-2518 ◽

Cited By ~ 2

Author(s):

Julio Rosenstock ◽

Antonio Nino ◽

Joseph Soffer ◽

Lois Erskine ◽

Andre Acusta ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Insulin Therapy ◽

Randomized Trial ◽

Receptor Agonist ◽

Prandial Insulin ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Faculty Opinions recommendation of Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.738371721.793577217 ◽

2020 ◽

Author(s):

John Tayek

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Insulin Therapy ◽

Randomized Trial ◽

Receptor Agonist ◽

Prandial Insulin ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Combination of Premixed Insulin with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) for Uncontrolled Type 2 Diabetes Mellitus (T2DM) Patients

Diabetes ◽

10.2337/db18-2231-pub ◽

2018 ◽

Vol 67 (Supplement 1) ◽

pp. 2231-PUB

Author(s):

SASAN FAZELI ◽

NICOLE EHRHARDT

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Receptor Agonist ◽

Premixed Insulin ◽

Glucagon Like Peptide ◽

938-P: The Relationship between Timing of Initiation on a Glucagon-Like Peptide-1 Receptor Agonist and HbA1c among Patients with Type 2 Diabetes

Diabetes ◽

10.2337/db20-938-p ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 938-P

Author(s):

RALEIGH E. MALIK ◽

REEMA MODY ◽

MAUREEN J. LAGE ◽

KRISTINA BOYE

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Timing Of Initiation ◽

The Relationship

Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies

Diabetes Therapy ◽

10.1007/s13300-021-01021-1 ◽

2021 ◽

Author(s):

Thomas M. Caparrotta ◽

Jack B. Templeton ◽

Thomas A. Clay ◽

Sarah H. Wild ◽

Rebecca M. Reynolds ◽

...

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Observational Studies ◽

Receptor Agonist ◽

Population Based ◽

Glucagon Like Peptide ◽

Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?

Clinical Diabetes ◽

10.2337/cd17-0065 ◽

2018 ◽

Vol 36 (2) ◽

pp. 138-147 ◽

Cited By ~ 4

Author(s):

Vanita R. Aroda ◽

Joseph R. Arulandu ◽

Anthony J. Cannon

Keyword(s):

Type 2 Diabetes ◽

Combination Therapy ◽

Receptor Agonist ◽

Two Agents ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Better Than

4324Effects of the glucagon like peptide-1 receptor agonist on arterial stiffness, LV myocardial deformation and oxidative stress in newly diagnosed type 2 diabetes after 6-month treatment

European Heart Journal ◽

10.1093/eurheartj/ehy563.4324 ◽

2018 ◽

Vol 39 (suppl_1) ◽

Author(s):

I Ikonomidis ◽

G Pavlidis ◽

V Lambadiari ◽

F Kousathana ◽

H Triantafyllidi ◽

...

Keyword(s):

Oxidative Stress ◽

Type 2 Diabetes ◽

Arterial Stiffness ◽

Receptor Agonist ◽

Myocardial Deformation ◽

Newly Diagnosed ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

And Oxidative Stress